Biogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees7,605
Employees7,605
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees7,605
Employees7,605
BIIB Key Statistics
Market cap18.23B
Market cap18.23B
Price-Earnings ratio11.67
Price-Earnings ratio11.67
Dividend yield—
Dividend yield—
Average volume1.66M
Average volume1.66M
High today$124.82
High today$124.82
Low today$115.75
Low today$115.75
Open price$119.39
Open price$119.39
Volume2.53M
Volume2.53M
52 Week high$238.00
52 Week high$238.00
52 Week low$110.04
52 Week low$110.04
BIIB News
Simply Wall St 6d
Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offeringappointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This mov...
Analyst ratings
57%
of 37 ratingsBuy
43.2%
Hold
56.8%
Sell
0%
People also own
Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.